NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Quantumzyme's Strategic Rebranding to Quantum Genesis AI
TL;DR
Quantumzyme Corp. plans to rename as Quantum Genesis AI Corp., positioning itself to gain market advantage in AI-driven sustainable pharmaceutical manufacturing.
The company integrates quantum mechanics, molecular modeling, and machine learning to engineer enzymes that streamline pharmaceutical production through computational design principles.
This technology aims to reduce chemical waste, minimize solvent use, and lower carbon intensity, making pharmaceutical manufacturing more environmentally sustainable.
Quantumzyme has developed enzymatic ibuprofen samples and published peer-reviewed research, showcasing innovative biocatalysts for greener pharmaceutical production.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantumzyme Corp. has announced that its Board of Directors has approved a proposed corporate name change to Quantum Genesis AI Corp., which will be submitted to FINRA for approval.
The rebranding reflects the company's strategic intent to align its identity more closely with its expanding integration of artificial intelligence into enzyme engineering initiatives, signaling a forward-looking approach to sustainable pharmaceutical production.
The proposed change will take effect only following FINRA approval, as the company must submit the required notice to FINRA first.
The company's proprietary technology framework integrates quantum mechanics, molecular modeling, machine learning, and computational design principles to develop biocatalysts for sustainable pharmaceutical manufacturing.
Specific design goals include supporting the reduction of chemical waste, minimizing solvent use, and lowering the carbon intensity associated with traditional pharmaceutical synthesis processes.
Recent achievements include laboratory-scale samples of enzymatic ibuprofen prepared for external evaluation and peer-reviewed research published in RSC Sustainability.
The company believes the strategic name change may enhance its visibility within markets focused on AI-driven innovation, sustainable chemistry, and domestic pharmaceutical manufacturing.
The company is assessing opportunities for partnerships, technology licensing, and collaborative development programs, which may provide pathways for revenue through licensing arrangements or joint development structures.
CEO Naveen Kulkarni stated that the proposed identity of Quantum Genesis AI represents the direction of the company's R&D efforts and aligns with combining intelligence-driven computational tools with sustainable chemistry.
The company's current ticker symbol is OTC: QTZM, and the notice to FINRA will include a request to update its ticker symbol as part of the name change process.
Curated from NewMediaWire
